https://orcid.org/0000-0002-5374-4412
References
- Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3(1):17026.
- Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894.
- Pollmann R, Schmidt T, Eming R, et al. Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clinic Rev Allerg Immunol. 2018;54(1):1–25.
- Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014;13(4–5):477–481.
- Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus–Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):20–32.
- Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–414.
- Harman KE, Brown D, Exton LS, et al. British association of dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170–1201.
- Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–1046.
- Pires CA, Viana VB, Araújo FC, et al. Evaluation of cases of pemphigus vulgaris and pemphigus foliaceus from a reference service in Pará state, Brazil. An Bras Dermatol. 2014;89(4):556–561.
- Fernandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus foliaceus experience with 71 patients over 20 year period. Rev Int Med Trop S Paulo. 2001;42(1):33–36.
- Shahidi-Dadras M, Karami A, Toosy P, et al. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. Arch Iran Med. 2007;10(1):1–6.
- Mignogna MD, Lo Muzio L, Ruoppo E, et al. High-dose intravenous ‘pulse’ methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med. 2002;31(6):339–344.
- Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother. 2008;9(9):1519–1530.
- Atzmony L, Hodak E, Leshem YA, et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264–271.
- Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–628.
- Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;1:CD006263.
- Kim MR, Kim HC, Kim SC. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Dermatology. 2011;223(2):182–188.
- Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138.
- Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545–552.
- Vinay K, Cazzaniga S, Amber KT, et al. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–808.
- Agarwal A, Hall RP, 3rd, Bañez LL, et al. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis. PLoS One. 2018;13(9):e0198074.
- Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol. 2018;pii: S0190-9622(18)30207-X.
- Wolf R, Landau M, Tur E, et al. Early treatment of pemphigus does not improve the prognosis. a review of 53 patients. J Eur Acad Dermatol Venereol. 1995;4(2):131–136.